TMS Co., Ltd. (JP:4891) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
TMS Co., Ltd., a clinical-stage biopharmaceutical company, is making strides with its promising lead program, TMS-007, aimed at treating acute ischemic stroke, a field that hasn’t seen a new drug in decades. The company’s CEO, Takuro Wakabayashi, highlighted this potential breakthrough and discussed an emerging pipeline addressing hypertension, kidney injury, and spinal cord injury during an interview on Biotech TV.
For further insights into JP:4891 stock, check out TipRanks’ Stock Analysis page.